Clinical Trial News and Research

RSS

Ongoing Phase I clinical trial demonstrates successful re-treatment with CAR T cell therapy

Researchers from the University of Pennsylvania's Abramson Cancer Center presented preliminary results of an ongoing Phase I clinical trial demonstrating successful re-treatment with CAR T cell therapy for patients whose cancers relapsed after previous CAR T therapy at the 2022 American Society of Hematology Annual Meeting.

12 Dec 2022

Off-the-shelf immunotherapy could offer new hope for patients with hard-to-treat multiple myeloma

A new therapy that makes the immune system kill bone marrow cancer cells was successful in as many as 73 percent of patients in two clinical trials, according to researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.

12 Dec 2022

Study shows potential benefits of efgartigimod as a treatment for immune thrombocytopenia

Patients taking efgartigimod, a drug being studied for use to treat chronic primary immune thrombocytopenia (ITP), exhibited a significantly greater improvement in platelet counts which are essential to clotting and stopping bleeding, compared to those taking a placebo, according to results reported from the ADVANCE IV clinical trial, which was conducted globally, including at Georgetown University Medical Center.

12 Dec 2022

ASCOT trial pinpoints most efficient level of blood thinning treatment for hospitalized COVID-19 patients

The COVID-19 global pandemic remains a major public health challenge. ASCOT researchers aim to discover which treatments are most effective in patients hospitalized with COVID-19.

12 Dec 2022

Researchers seek to reduce Chikungunya virus-caused joint pain with new drug

Oregon Health & Science University researchers and partners are developing what could become the first-ever treatment against the debilitating joint pain that can last months or years after becoming infected with the emerging Chikungunya virus.

9 Dec 2022

Study may allow patients with multiple breast lesions to consider breast-conserving therapy as treatment option

Patients with multiple tumors in the same breast who underwent a lumpectomy followed by radiation therapy had local recurrence rates comparable to those historically observed in patients with a single tumor, according to results from the ACOSOG Z11102 (Alliance) prospective phase II clinical trial, which were presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

9 Dec 2022

Scientists trace how livestock systems act as a reservoir for antimicrobial-resistant bacteria

Scientists from the International Livestock Research Institute (ILRI), the University of Liverpool, the University of Edinburgh and elsewhere have traced how livestock systems act as a reservoir for antimicrobial-resistant (AMR) bacteria and AMR genetic determinants that may infect or colonize people.

9 Dec 2022

Addition of capivasertib to fulvestrant doubles progression-free survival in HR-positive breast cancer patients

In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational AKT inhibitor capivasertib to fulvestrant (Faslodex) doubled the median progression-free survival compared with placebo plus fulvestrant in the phase III CAPItello-291 clinical trial, according to results presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

9 Dec 2022

Estrogen replacement therapy may be a tool to mitigate delirium

Delirium is common among women with urinary tract infections (UTIs) - especially those who have experienced menopause.

8 Dec 2022

Therapeutic activation of p53 could offer new treatment option for salivary gland cancer

Researchers at the University of Michigan Rogel Cancer Center and School of Dentistry found that certain drugs can change the fundamental makeup of cancer stem cells in mouse models of mucoepidermoid carcinoma – a lethal form of salivary gland cancer that currently has no treatment options.

8 Dec 2022

Multi-stage HIV vaccine regimen shows promising results in Phase 1 clinical trial

The George Washington University Vaccine Research Unit in partnership with Scripps Research, IAVI, Fred Hutchinson Cancer Center (FHCC) and the National Institutes of Health, National Institute of Allergy and Infectious Diseases Vaccine Research Center published the results of their Phase 1 Clinical Trial in Science.

8 Dec 2022

For patients with sickle cell disease, fertility care is about reproductive justice

Teonna Woolford has always wanted six kids. Why six? "I don't know where that number came from. I just felt like four wasn't enough," said Woolford, a Baltimore resident. "Six is a good number."

8 Dec 2022

Updated results on a new approach to treating advanced ER-positive/HER2-negative breast cancer

A UCLA Jonsson Comprehensive Cancer Center researcher and collaborators in a multicenter study will present updated results and plans for further research on a new approach to treating advanced ER-positive/HER2-negative breast cancer.

7 Dec 2022

UK's Newton Fund supported Mexican scientist to develop vaccines against Chikungunya, Zika and Dengue

Dr Arturo Reyes Sandoval is the Director of the National Polytechnic Institute, one of the largest and most prestigious universities in Mexico.

7 Dec 2022

T-DXd leads to longer overall survival in HER2-positive metastatic breast cancer patients than T-DM1

Second-line treatment with trastuzumab deruxtecan (T-DXd) led to significantly longer overall survival compared with trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer, according to updated results from the DESTINY-Breast03 phase III clinical trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

7 Dec 2022

T-DXd shows high efficacy in HER2-positive breast cancer patients previously treated with T-DM1

Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd) led to higher response rates and longer survival in the third-line setting for patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine (T-DM1), according to results from the phase III DESTINY-Breast02 trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

7 Dec 2022

Researchers share results of MVA-BN-respiratory syncytial virus vaccine human challenge trial

Researchers reported the immunogenicity, efficacy, and safety of the MVA-BN (modified vaccinia Ankara-Bavarian Nordic)-RSV (respiratory syncytial virus) vaccine against RSV-A (RSV subtype A) Memphis 37b strain in a human challenge trial.

7 Dec 2022

Study allows people with type 2 diabetes to choose their own medication

A large-scale new study offers a new approach to treating type 2 diabetes - that puts patients in charge of their own medication. The Trimaster study is the first to allow people with type 2 diabetes to choose their own medication, after trying three different drugs in succession.

7 Dec 2022

Study reports overall response of HER2-low breast cancer patients to neoadjuvant T-DXd treatment

Patients with localized, hormone receptor-positive, HER2-low breast cancer treated with trastuzumab deruxtecan (T-DXd, Enhertu) in the neoadjuvant setting had an overall response rate of 75 percent in the absence of anastrozole and 63 percent in combination with anastrozole, according to results from the phase II TRIO-US B-12 TALENT trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

7 Dec 2022

Exploring immunogenicity, boosting efficacy and safety of modified vaccinia Ankara-Bavarian Nordic vaccine

Researchers evaluated the immunogenicity, boosting efficacy, and safety of single-dose and two-dose MVA-BN (modified vaccinia Ankara-Bavarian Nordic) vaccinations in comparison to replicating smallpox vaccines.

7 Dec 2022

Clinical Trial News and Research

Ongoing Phase I clinical trial demonstrates successful re-treatment with CAR T cell therapy

Off-the-shelf immunotherapy could offer new hope for patients with hard-to-treat multiple myeloma

Study shows potential benefits of efgartigimod as a treatment for immune thrombocytopenia

ASCOT trial pinpoints most efficient level of blood thinning treatment for hospitalized COVID-19 patients

Researchers seek to reduce Chikungunya virus-caused joint pain with new drug

Study may allow patients with multiple breast lesions to consider breast-conserving therapy as treatment option

Scientists trace how livestock systems act as a reservoir for antimicrobial-resistant bacteria

Addition of capivasertib to fulvestrant doubles progression-free survival in HR-positive breast cancer patients

Estrogen replacement therapy may be a tool to mitigate delirium

Therapeutic activation of p53 could offer new treatment option for salivary gland cancer

Multi-stage HIV vaccine regimen shows promising results in Phase 1 clinical trial

For patients with sickle cell disease, fertility care is about reproductive justice

Updated results on a new approach to treating advanced ER-positive/HER2-negative breast cancer

UK's Newton Fund supported Mexican scientist to develop vaccines against Chikungunya, Zika and Dengue

T-DXd leads to longer overall survival in HER2-positive metastatic breast cancer patients than T-DM1

T-DXd shows high efficacy in HER2-positive breast cancer patients previously treated with T-DM1

Researchers share results of MVA-BN-respiratory syncytial virus vaccine human challenge trial

Study allows people with type 2 diabetes to choose their own medication

Study reports overall response of HER2-low breast cancer patients to neoadjuvant T-DXd treatment

Exploring immunogenicity, boosting efficacy and safety of modified vaccinia Ankara-Bavarian Nordic vaccine

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer